Paysign, Inc. (PAYS) closed the last trading session at $5.09, gaining 42.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $7.35 indicates a 44.4% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $0.74. While the lowest estimate of $6.50 indicates a 27.7% increase from the current price level, the most optimistic analyst expe ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Paysign (PAYS) Conference June 04, 2025 03:00 PM ET Speaker0 Ladies and gentlemen in attendance and to our webinar guests around the world, welcome back to the two thousand twenty five Microcap Rodeo. Next up, it is the CFO of PaySign Inc. I give you mister Jeff Baker. Jeff, come on up here. Speaker1 Thank you very much. Jeff, as he said, my name is Jeff Baker, CFO, PaySign. I've been with the company just over four years. Happy to present the company's listed on the Nasdaq under the symbol PAYS. Some forwa ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 2615 St. Rose Parkway, Henderson, Nevada 89052 (Address of ...

Paysign (PAYS) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Mark Newcomer - Co-Founder, President, CEO & ChairmanJeff Baker - CFO Operator Good afternoon. My name is Chelsea, and I will be your conference operator today. At this time, I would like to welcome everyone to the PaySign, Inc. First Quarter twenty twenty five Earnings Conference Call. After the speakers' remarks, there will be a question and answer session. As a reminder, this conference is being recorded. The comments on t ...

Paysign (PAYS) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good afternoon. My name is Chelsea, and I will be your conference operator today. At this time, I would like to welcome everyone to the PaySign, Inc. First Quarter twenty twenty five Earnings Conference Call. After the speakers' remarks, there will be a question and answer session. As a reminder, this conference is being recorded. The comments on today's call regarding PaySign's financial results will be on a GAAP basis unless otherwise ...

Exhibit 99.1 Earnings Release Paysign, Inc. Reports First Quarter 2025 Financial Results Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted EBITDA at the end of the press release. HENDERSON, Nev. – May 8, 2025 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services an ...

公司业务规划与市场目标 - 公司计划2025年继续在技术改进、销售和营销、网络安全、欺诈防范、客户服务和监管合规方面投入资金[149][163] - 公司预计回购计划将在开始日期起36个月内完成[149] - 公司认为2025年至2027年的可用现金、收入和现金流预测足以维持未来24个月的运营[149] - 公司开放式礼品卡业务于2022年底开始，制药预付业务于2022年结束[153] - 公司目前营销重点是企业激励和费用预付卡产品[160] - 公司通过直接营销推广支付解决方案，可能会利用独立承包商进行直销[162] - 公司评估新技术适用性，目标市场包括美国和墨西哥的预付卡发行商等[161] 公司业务线产品情况 - 公司有可reloadable和non - reloadable两类预付借记卡[154] - 公司管理预付卡生命周期的各个方面，拥有24/7/365的内部客服部门[159] 公司业务线数据指标 - 截至2024年12月31日，公司持卡人约达730万，卡计划约600个[164] - 2024年全年总收入为5838.4552万美元，较上一年增加1111.039万美元，同比增长23.5%，其中血浆行业收入4387.9508万美元，同比增长4.6%；制药行业收入1265.2412万美元，同比增长212.3%；其他收入185.2632万美元，同比增长45.7%[165] - 2024年全年毛利润为3219.7334万美元，较上一年增加806.1169万美元，同比增长33.4%，毛利率从51.1%提升至55.1%[165] - 2024年全年净收入为381.5907万美元，较上一年减少264.282万美元，同比下降40.9%，净利率从13.7%降至6.5%[165] - 2024年和2023年加载到卡上的总美元交易量分别为17.83亿美元和17.06亿美元，总收入转化率分别为3.27%和2.77%，总毛利润转化率分别为1.81%和1.41%，净收入转化率分别为0.21%和0.38%[173][174] - 2024年调整后EBITDA为962.1083万美元，2023年为671.2966万美元，调整后EBITDA利润率分别为16.5%和14.2%[176][178] 公司现金流数据指标 - 2024年经营活动提供的净现金为2294.712万美元，较2023年减少467.3504万美元[179][181] - 2024年和2023年投资活动使用的净现金分别为948.8702万美元和704.8678万美元[179][182] - 2024年融资活动使用的净现金为46.6245万美元，2023年为111.8284万美元[179] - 2024年现金及受限现金净增加1299.2173万美元，2023年为1945.3662万美元[179] - 2024年和2023年融资活动所用现金分别为466,245美元和1,118,284美元，2024年回购136,700股普通股，加权平均股价3.62美元/股，股票期权行权收入28,800美元；2023年回购394,558股普通股，加权平均股价2.86美元/股，股票期权行权收入9,600美元[183] - 截至2024年12月31日，无限制现金为10,766,982美元，较上年同期减少6,227,723美元，主要因患者负担业务的直通索赔报销应收款和相关应付款支付时间影响，金额为7,018,053美元，被经营业绩改善抵消[185] 公司会计政策 - 有限使用寿命的无形资产按直线法在3至15年的估计使用寿命内摊销[188] - 内部使用软件开发的初步项目和实施后阶段成本在发生时费用化，应用和开发阶段成本资本化，按直线法在三年估计使用寿命内摊销[189] 公司收入确认原则 - 公司收入包括持卡人费用、交换费、卡计划管理费、交易索赔处理费、破损收入和结算收入[153] - 持卡人费用在履行履约义务时确认；卡计划管理费用和交易索赔处理费用通常按月赚取时确认，一般30天内到期；交换费在处理卡交易时确认，通常几天内结算[194] - 对于预计有权获得破损金额的卡计划，公司使用估计破损率在估计卡寿命内按比例确认收入[195] - 公司对结算收入采用远程确认法，未使用余额在卡或卡计划到期时确认为收入，主要与2022年结束的制药预付业务相关[196] 公司租赁与股权补偿政策 - 公司确定合同是否包含租赁要素，经营租赁负债基于未来租赁付款的现值，初始期限12个月及以下的租赁不记录在资产负债表上[197][199] - 公司对所有限制性股票奖励和股票期权确认补偿费用，限制性股票奖励公允价值按授予日股价计量，股票期权公允价值使用Black - Scholes期权定价模型估计[200] 公司收入业务构成 - 公司通过血浆卡计划、制药卡计划及其他业务产生收入，血浆和制药卡计划收入包括固定和可变部分[193]

Paysign (PAYS) Q4 2024 Earnings Call March 25, 2025 11:27 PM ET Company Participants Mark Newcomer - Co-Founder, President, CEO & ChairmanJeffery Baker - CFO & TreasurerGary Prestopino - Managing DirectorMatthew Turner - President of Patient AffordabilityPeter Heckmann - MD - Equity ResearchMatthew Lanford - Chief Payments Officer Conference Call Participants Jacob Stephan - Senior Research Analyst Operator Good afternoon. My name is Kevin, and I'll be your conference operator today. At this time, I'd like ...